🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT05628129
Active, not recruiting Not applicable

Effect of Mobile Communication on Congenital Ectopia Lentis Follow-up Adherence

NCT05628129 · tracked via the Priya Life Science China tracker
Sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Phase
Not applicable
Started
2022-12-05
Last updated
2025-02-13

Condition(s) studied

Ectopia Lentis

Investigational drug(s) / intervention(s)

smartphone application service and phone reminder

smartphone application service and phone reminder: smartphone application service and phone reminder for appointments of parents of congenital ectopia lentis patients

Study summary

Regular follow-up is essential to successful management of congenital ectopia lentis, but it is often ignored by parents in China.

With rapid economic development, there are increasing numbers of mobile phone users that allow for communication applications to be used in medical care.

The investigators aimed to assess the potential of the smartphone application assisted medical service to increase patient compliance in attendance of follow-up after congenital ectopia lentis treatment.

Eligibility

Sex
ALL
Min age
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * 1\. Identified with congenital lens dislocation after surgery and age ≤ 18 years old; 2. Parents were able to access a mobile phone and communicate via the smartphone application (WeChat); 3. Agree to participate in this study and sign the informed consent. Exclusion Criteria: * 1\. With Other ophthalmic diseases such as glaucoma, uveitis and corneal disease.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Zhongshan Ophthalmic Center, Sun Yat-sen University Guangzhou Guangdong

More Zhongshan Ophthalmic Center, Sun Yat-sen University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05628129 on ClinicalTrials.gov ↗ ← All trials in China